Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
93 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hairy Cell Leukemia - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hairy Cell Leukemia - Pipeline Review, H2 2016, provides an overview of the Hairy Cell Leukemia (Oncology) pipeline landscape. Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hairy Cell Leukemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Hairy Cell Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hairy Cell Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 8, 1, 1, 2 and 1 respectively.Hairy Cell Leukemia. Hairy Cell Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia (Oncology). - The pipeline guide reviews pipeline therapeutics for Hairy Cell Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Hairy Cell Leukemia (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Hairy Cell Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Hairy Cell Leukemia (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Hairy Cell Leukemia (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Hairy Cell Leukemia (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Hairy Cell Leukemia Overview 7 Therapeutics Development 8 Pipeline Products for Hairy Cell Leukemia - Overview 8 Hairy Cell Leukemia - Therapeutics under Development by Companies 9 Hairy Cell Leukemia - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Unknown Stage Products 13 Hairy Cell Leukemia - Products under Development by Companies 14 Hairy Cell Leukemia - Companies Involved in Therapeutics Development 15 AbbVie Inc 15 ARA Healthcare Pvt. Ltd. 16 Astellas Pharma Inc. 17 Biogenomics Limited 18 F. Hoffmann-La Roche Ltd. 19 Incyte Corporation 20 Juno Therapeutics Inc. 21 MedImmune LLC 22 Novartis AG 23 Hairy Cell Leukemia - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Combination Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 (dezapelisib + itacitinib adipate) - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 AGS-67E - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 ARABS-4 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 dezapelisib - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 ibrutinib - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 INCB-50465 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 interferon alfa-2a - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 interferon alfa-2b - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 interferon alfa-2b - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 itacitinib adipate - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 JCAR-015 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 moxetumomab pasudotox - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 vemurafenib - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 Hairy Cell Leukemia - Dormant Projects 88 Hairy Cell Leukemia - Discontinued Products 89 Hairy Cell Leukemia - Product Development Milestones 90 Featured News & Press Releases 90 Oct 09, 2016: ESMO 2016: Vemurafenib Shows Clinical Benefit in Diverse BRAF V600-Mutated Tumors 90 May 16, 2013: AstraZeneca's MedImmune Enrolls First Patient In Phase III Leukemia Trial Of Moxetumomab Pasudotox 91 Appendix 92 Methodology 92 Coverage 92 Secondary Research 92 Primary Research 92 Expert Panel Validation 92 Contact Us 92 Disclaimer 93
List of Tables Number of Products under Development for Hairy Cell Leukemia, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Comparative Analysis by Unknown Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Hairy Cell Leukemia - Pipeline by AbbVie Inc, H2 2016 15 Hairy Cell Leukemia - Pipeline by ARA Healthcare Pvt. Ltd., H2 2016 16 Hairy Cell Leukemia - Pipeline by Astellas Pharma Inc., H2 2016 17 Hairy Cell Leukemia - Pipeline by Biogenomics Limited, H2 2016 18 Hairy Cell Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 19 Hairy Cell Leukemia - Pipeline by Incyte Corporation, H2 2016 20 Hairy Cell Leukemia - Pipeline by Juno Therapeutics Inc., H2 2016 21 Hairy Cell Leukemia - Pipeline by MedImmune LLC, H2 2016 22 Hairy Cell Leukemia - Pipeline by Novartis AG, H2 2016 23 Assessment by Monotherapy Products, H2 2016 24 Assessment by Combination Products, H2 2016 25 Number of Products by Stage and Target, H2 2016 27 Number of Products by Stage and Mechanism of Action, H2 2016 29 Number of Products by Stage and Route of Administration, H2 2016 31 Number of Products by Stage and Molecule Type, H2 2016 33 Hairy Cell Leukemia - Dormant Projects, H2 2016 88 Hairy Cell Leukemia - Discontinued Products, H2 2016 89
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.